VANCOUVER, British Columbia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that David Main, Aquinox's Chief Executive Officer, will present at the upcoming Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14 at 3:00 PM Eastern Time. The conference will take place at the InterContinental Boston in Boston, MA.
A live audio webcast and archive of the event will be available at http://wsw.com/webcast/canaccord14/aqxp. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of Aquinox's website for at least two weeks following the presentation.
The corporate overview being presented will be available at www.aqxpharma.com.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc. is a clinical stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer. For more information please visit www.aqxpharma.com.
CONTACT: Brendan Payne Senior Manager, Investor Relations Aquinox Pharmaceuticals, Inc. 604.629.9223 Ext. 109 email@example.com Bianca Nery Senior Account Executive MacDougall Biomedical Communications 650.339.7533 firstname.lastname@example.org
Source:Aquinox Pharmaceuticals, Inc.